Immunohistochemical detection of steroid receptors in breast cancer: a working protocol

Leake, Robin

doi:10.1136/jcp.53.8.634

Cited by 167 publications

(77 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunohistochemical Analysis (IHC) [5][6][7] A single section showing both tumor and preferably with the adjacent uninvolved breast tissue was routinely submitted for immunohistochemistry, and stained with antibodies against ER (Immunotech, clone1D5) and PR (Immunotech, clone PR636). At molecular medicine, RLS, LSAB peroxidase based detection system is used for IHC.…”

Section: Histologic Examinationmentioning

confidence: 99%

Study of Hormone Receptors and Epidermal Growth Factor Expression in Invasive Breast Cancers in a Cohort of Western India

Dodiya¹,

Patel²,

Patel³

et al. 2013

Ind J Clin Biochem

View full text Add to dashboard Cite

The objective of study was to evaluate and correlate the pathological characteristics of breast cancer patients with estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2/neu) detected by immunohistochemistry and/or fluorescent in situ hybridization method. We have conducted 2 year study of 204 cases of breast cancer at HCG-Medisurge Hospitals, Ahmedabad from 2009 to 2011. Significant correlation was found in ER and PR expression whereas no correlation was found in hormonal receptors and Her2/neu expression. ER and PR positivity increased with advancing age in breast carcinoma patients while not affecting Her2/neu expression. The expression of hormone receptors were higher in infiltrating lobular carcinoma and infiltrating duct carcinoma subtypes of breast carcinoma as compared to other subtypes such medullary and in situ carcinoma. High-grade carcinoma patients were predominantly ER/PR negative and Her2/neu positive as compared to lower grade breast carcinoma whereas high-stage carcinoma patients were ER/PR positive and Her2/neu positive as compared to lower stage breast carcinoma.

show abstract

Section: Histologic Examinationmentioning

confidence: 99%

Study of Hormone Receptors and Epidermal Growth Factor Expression in Invasive Breast Cancers in a Cohort of Western India

Dodiya¹,

Patel²,

Patel³

et al. 2013

Ind J Clin Biochem

View full text Add to dashboard Cite

show abstract

“…Tissue controls included prostate, breast and thyroid tissues for AR, Rab25 and Rab35, respectively. Each core was independently scored by two of the authors (EMA and RJE) using a modified H-score (Leake et al, 2000). The H-score is a multiplicative score generated by two parameters, namely maximal intensity of staining and percentage area of the section stained.…”

Section: Immunohistochemistrymentioning

confidence: 99%

Androgen-related expression of G-proteins in ovarian cancer

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: Epidemiological and in vitro data implicate androgens in the aetiology of ovarian cancer, but the mechanisms by which this is mediated are unclear. In this study, we wished to examine the effects of androgens on gene expression in ovarian cancer. METHODS: The expression of androgen receptor (AR) in OVCAR3 and OSEC2 cells was confirmed using immunoblotting and response to androgens was measured using flow cytometric assessment of S-phase fraction. The differential gene expression between androgen stimulated and unstimulated OVCAR3 ovarian cancer cells was examined with a cDNA microarray. The upregulation of a subset of these genes was then confirmed with reverse transcriptase PCR in both OVCAR3 and OSEC2, an ovarian epithelial cell line. Finally, the clinical significance of this upregulation was investigated by examining the expression of Rab25 and Rab35, two G-protein-related molecules in an ovarian cancer tissue microarray (TMA). RESULTS: OVCAR3 and OSEC2 cells were shown to express the AR and showed an increase in S-phase fraction in response to androgen treatment. Treatment of OVCAR3 cells with androgen resulted in a significant upregulation of 121 genes. These findings were confirmed for a subset of seven monomeric G-protein-related genes in both OVCAR3 and OSEC2 cells. After staining for Rab25 and Rab35, the majority of TMA sections examined showed expression for Rab25 (92%) and Rab35 (95%). The expression of Rab25 correlated with histological grade, and expression was higher in endometrioid (median histoscore 10.5) than serous (7.5) or mucinous (5.3) tumours. The expression of Rab25 correlated positively with AR expression supporting its role as an androgen responsive gene in ovarian cancer. CONCLUSIONS: These results suggest that androgens can effect expression of the oncogenic GTPases in ovarian cancer. We propose that the androgen responsive Rab35 may have clinical importance as a biomarker of AR function.

show abstract

“…Quantitation was based on a scoring system reported in detail previously (Allred et al, 1998;Leake et al, 2000). This method is based on a composite additive score of intensity 0 -3 and the proportion of malignant epithelial cells staining 0 -5.…”

Section: Quantitation Of Immunohistochemical Stainingmentioning

confidence: 99%

Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment

et al. 2006

View full text Add to dashboard Cite

In order to elucidate the relative importance of oestrogen receptor (ER)a, ERb and an ERb variant (ERb2/bcx) in the response of breast cancers to tamoxifen, tumour levels of each receptor were assessed in 36 patients before and after 3 months of neoadjuvant treatment with tamoxifen (20 mg daily). All patients were postmenopausal women presenting with large ERa-positive breast cancers. Clinical response to treatment was assessed by tumour volume changes as determined from sequential ultrasounds and pathological response by comparison of the tumour morphology before and after treatment. Of 33 cases, 23 (70%) were classified as having a clinical response and 16 (48%) as having a response pathologically. All tumours stained positively for ERa and ERb and 15 out of 33 (45%) for ERb2/bcx. There were no significant differences in quantitative expression of any receptor between tumours that subsequently responded and that did not, whether response was assessed clinically or pathologically. Tamoxifen treatment was associated with a decrease in ERa, but an increase was the most frequent change (17 out of 33) in ERb, and no consistent change was evident in staining of the ERb2/bcx variant. In summary, ERb1 and ERb2/bcx variant protein are detected in ERa-positive breast tumours but their expression is not associated with a response to tamoxifen. Differential changes in ERa and ERb were seen with treatment.

show abstract

Immunohistochemical detection of steroid receptors in breast cancer: a working protocol

Cited by 167 publications

References 3 publications

Study of Hormone Receptors and Epidermal Growth Factor Expression in Invasive Breast Cancers in a Cohort of Western India

Study of Hormone Receptors and Epidermal Growth Factor Expression in Invasive Breast Cancers in a Cohort of Western India

Androgen-related expression of G-proteins in ovarian cancer

Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment

Contact Info

Product

Resources

About